145
Views
0
CrossRef citations to date
0
Altmetric
Research Articles

Solubilization of a novel antitumor drug ribociclib in water and ten different organic solvents at different temperatures

, & ORCID Icon
Pages 12-20 | Received 01 Aug 2021, Accepted 08 Jun 2022, Published online: 21 Jun 2022
 

Abstract

Objective

This study reports new solubility and physicochemical data for ribociclib (RCB) in water and ten organic solvents including “methanol (MeOH), ethanol (EtOH), isopropyl alcohol (IPA), n-butanol (n-BuOH), propylene glycol (PG), polyethylene glycol-400 (PEG-400), acetone, ethyl acetate (EA), Transcutol-HP (THP), and dimethyl sulfoxide (DMSO)” at 293.2–313.2 K and 101.1 kPa.

Significance

The obtained data are useful for the industrial applications of RCB.

Methods

The solubility of RCB was measured and regressed using “van’t Hoff, Buchowski-Ksiazczak λh, the modified Apelblat, and Jouyban models.”

Results

The overall deviations of <4.0% were recorded for all four models. The maximum mole fraction solubility of RCB was 2.66 × 10−2 in PEG-400 at 313.2 K, however, the lowest one was in the water. The RCB solubility increased with temperature and the order followed in the water and ten different organic solvents was PEG-400 (2.66 × 10−2) > THP (1.00 × 10−2) > PG (5.39 × 10−3) > DMSO (5.00 × 10−3) > n-BuOH (3.23 × 10−3) > acetone (3.11 × 10−3) > IPA (1.58 × 10−3) > EA (1.41 × 10−3) > EtOH (1.37 × 10−3) > MeOH (8.10 × 10−4) > water (2.38 × 10−5) at 313.2 K. The maximum solute-solvent interactions were found in RCB-PEG-400 in comparison with other combination of RCB and solvents. “Apparent thermodynamic analysis” indicated an “endothermic and entropy-driven dissolution” of RCB in water and ten organic solvents.

Conclusions

Based on all these data and observations, PEG-400 can be used as the best co-solvent for RCB solubilization.

Disclosure statement

The authors declare no conflict of interest.

Additional information

Funding

This project was supported by the Scientific Research Support Fund (SRSF) & Innovation, the Hashemite Kingdom of Jordan, under research project No. MPH/1/4/2019.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.